Anti-CD19 strategies in hematological malignancies Journal Article


Authors: Leslie, L.; Younes, A.
Article Title: Anti-CD19 strategies in hematological malignancies
Abstract: Differentiation antigen CD19 (CD19) is a surface protein with an important role in both normal and malignant B-cell physiology. CD19 is an attractive target for novel immunotherapies in B-cell hematopoietic malignancies, as it is B cell-specific with few exceptions, widely and reliably expressed on malignant and normal B cells, and absent from pluripotent stem cells, as well as terminally differentiated plasma cells. A variety of approaches to anti-CD19 therapy have been explored, with several new techniques on the horizon. In this review, we discuss various methods of targeting CD19, including modified monoclonal antibodies, Fc-engineered antibodies, radioimmunotherapeutics, antibody-drug conjugates, bispecific agents and anti-CD19 chimeric antigen receptor (CAR) T cells. Copyright © 2013 Prous Science, S.A.U. or its licensors. All rights reserved.
Keywords: monoclonal antibodies; hematological malignancies; antibody-drug conjugates; anti-cd19 strategies; radioimmunotherapeutics; bispecific agents
Journal Title: Drugs of the Future
Volume: 38
Issue: 12
ISSN: 0377-8282
Publisher: Prous Science  
Date Published: 2013-01-01
Start Page: 835
End Page: 843
Language: English
DOI: 10.1358/dof.2013.38.12.2076503
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 3 March 2014 -- CODEN: DRFUD -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Anas Younes
    250 Younes